[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336610-105":59,"doc-detail-336610-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pd-1lag-3-co-signaling-proling-uncovers-cbl-ubiquitin-ligases-as-key-immunotherapy-targets","PD-1/LAG-3 co-signaling proﬁling uncovers CBL ubiquitin ligases as key immunotherapy targets","","Many cancer patients fail to benefit from PD-L1/PD-1 blockade immunotherapies. PD-1 and LAG-3 co-upregulation in T cells drives resistance by inducing a highly dysfunctional T-cell state. Multiomic profiling across TCGA immune infiltrates identifies a PD-1/LAG-3 dysfunctional signature controlling immune, metabolic, genetic, and epigenetic programs, with reinforced suppression of the TCR signalosome. Proteomic analysis enriches ubiquitin ligases in E3 ubiquitination pathways, and CBL ubiquitin ligases emerge as actionable targets for reversing dysfunction and overcoming mediated resistance.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pd-1lag-3-co-signaling-proling-uncovers-cbl-ubiquitin-ligases-as-key-immunotherapy-targets/336610/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pd-1lag-3-co-signaling-proling-uncovers-cbl-ubiquitin-ligases-as-key-immunotherapy-targets/336610.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do some cancer patients not respond to PD-L1/PD-1 blockade immunotherapies?","Question",{"text":112,"@type":113},"Resistance is driven by mechanisms that establish a dysfunctional T-cell state, especially through co-expression and co-upregulation of LAG-3 with PD-1 in T cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What was identified as a key feature of PD-1/LAG-3 dysfunction in cancers?",{"text":117,"@type":113},"A PD-1/LAG-3 dysfunctional signature that regulates immune, metabolic, genetic, and epigenetic pathways, with especially reinforced negative regulation of the TCR signalosome.",{"name":119,"@type":110,"acceptedAnswer":120},"How do CBL ubiquitin ligases relate to overcoming PD-1/LAG-3 resistance?",{"text":121,"@type":113},"PD-1/LAG-3 co-blockade inhibits CBL-B expression, and targeting CBL-B with small molecule inhibitors combined with anti-PD-1/anti-LAG-3 immunotherapies shows therapeutic efficacy in lung cancer models resistant to immunotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336610,1790604343,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nPD-1/LAG-3 co-signaling proﬁling uncovers CBL ubiquitin ligases as key immunotherapy targets  \nLuisa Chocarro 1,7 ✉ , Ester Blanco1,2,7, Leticia Fernandez-Rubio1, Maider Garnica 1, Miren Zuazo1, Maria Jesus Garcia1, Ana Bocanegra 1, Miriam Echaide1, Colette Johnston3, Carolyn J Edwards3, James Legg 3, Andrew J Pierce 3, Hugo Arasanz 4,5, Gonzalo Fernandez-Hinojal4, Ruth Vera  Karina Ausin 6, Enrique Santamaria6, Joaquin Fernandez-Irigoyen 6, Grazyna Kochan 1 & David Escors 1 ✉  \n4  \n,  \nAbstract  \nMany cancer patients do not beneﬁt from PD-L1/PD-1 blockade immunotherapies. PD-1 and LAG-3 co-upregulation in T-cells is oneof the major mechanisms of resistance by establishing a highly dysfunctional state in T-cells. To identify shared features associated to PD-1/LAG-3 dysfunctionality in human cancers and Tcells, multiomic expression proﬁles were obtained for all TCGA cancers immune inﬁltrates. A PD-1/LAG-3 dysfunctional signature was found which regulated immune, metabolic, genetic, and epigenetic pathways, but especially a reinforced negative regulation of the TCR signalosome. These results were validated in T-cell lines with constitutively active PD-1, LAG-3 pathways and their combination. A differential analysis of the proteome of PD-1/LAG-3 T-cells showed a speciﬁc enrichment in ubiquitin ligases participating in E3 ubiquitination pathways. PD-1/LAG-3 co-blockade inhibited CBL-B expression, while the use of a bispeciﬁc drug in clinical development also repressed C-CBL expression, which reverted T-cell dysfunctionality in lung cancer patients resistant to PD-L1/PD-1 blockade. The combination of CBL-B-speciﬁc small molecule inhibitors with anti-PD-1/anti-LAG-3 immunotherapies demonstrated notable therapeutic efﬁcacy in models of lung cancer refractory to immunotherapies, overcoming PD-1/LAG-3 mediated resistance.  \nKeywords Cancer Immunotherapy; CBL Ubiquitin Ligases; LAG-3; PD-1; T-cell Dysfunctionality  \nSubject Categories Cancer; Chromatin, Transcription & Genomics; Immunology  \n[https://doi.org/10.1038/s44321-024-00098-y](https://doi.org/10.1038/s44321-024-00098-y)  \nReceived 12 January 2024; Revised 13 June 2024; Accepted 21 June 2024  \nPublished online: 19 July 2024  \nIntroduction  \nPD-L1/PD-1 immune checkpoint (IC) blockade has revolutionised oncology (Topalian et al, 2015; Topalian et al, 2016) . This strategy reactivates cancer-speciﬁc T-cells leading to tumor regression or long-term disease control. However, intrinsic resistance to PD-L1/ PD-1 blockade frequently occurs through several mechanisms. Oneof the most relevant is the co-expression of LAG-3 with PD-1 in Tcells, which establishes strong T-cell dysfunctionality in patients leading to resistance to conventional immunotherapies, as we and others have shown (Chocarro et al, 2022a; Zuazo et al, 2020; Zuazo et al, 2019) . T-cell dysfunctionality was partially overcome ex vivo with PD-1 and LAG-3 co-blockade in T-cells from non-small cell lung cancer (NSCLC) patients, which recovered proliferative and effector activities (Edwards et al, 2022; Zuazo et al, 2019) . Hence, PD-1 and LAG-3 cooperatively establish a strong dysfunctional state in T-cells possibly through co-signaling. The mechanisms by which PD-1 interferes with T-cell functions are well-known and reviewed elsewhere (Arasanz et al, 2017) . Brieﬂy, PD-1 signaling terminates T-cell receptor (TCR) signal transduction, causes its down-modulation and degradation, and impacts on T-cell metabolism (Chemnitz et al, 2004; Hui et al, 2017; Karwacz et al, 2011; Patsoukis et al, 2015; Patsoukis et al, 2013; Plas et al, 1996; Sheppard et al, 2004) . However, the speciﬁc inhibitory mechanisms regulated by LAG-3, and the combined effects of PD-1 and LAG-3 co-signaling are largely unknown (Edwards et al, 2022; Zuazo et al, 2019) . It has been suggested that PD-1 and LAG-3 establish a complex together with TCR components, that would be required for their combined inhibitory activities (Chen and Flies, 2013; Hann","cbCaihxKkLrhUwbc","https://ap.wps.com/l/cbCaihxKkLrhUwbc","pdf",9448203,26,"English","# Abstract\n# Introduction","[{\"question\":\"Why do some cancer patients not respond to PD-L1/PD-1 blockade immunotherapies?\",\"answer\":\"Resistance is driven by mechanisms that establish a dysfunctional T-cell state, especially through co-expression and co-upregulation of LAG-3 with PD-1 in T cells.\"},{\"question\":\"What was identified as a key feature of PD-1/LAG-3 dysfunction in cancers?\",\"answer\":\"A PD-1/LAG-3 dysfunctional signature that regulates immune, metabolic, genetic, and epigenetic pathways, with especially reinforced negative regulation of the TCR signalosome.\"},{\"question\":\"How do CBL ubiquitin ligases relate to overcoming PD-1/LAG-3 resistance?\",\"answer\":\"PD-1/LAG-3 co-blockade inhibits CBL-B expression, and targeting CBL-B with small molecule inhibitors combined with anti-PD-1/anti-LAG-3 immunotherapies shows therapeutic efficacy in lung cancer models resistant to immunotherapy.\"}]","PD-1/LAG-3 co-signaling proﬁling uncovers CBL ubiquitin ligases as key immunotherapy targets | PDF",1790015848,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/667ac54f79f98f87c8f42d183f04cc81.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e56d7537e21d1c8a9b40d80d91e8427.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1f9077b0e56465f995b6ceca9e7e3fe.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3f0108da8bf1d0e5045c9d18ecadc0d.webp",980,1301]